Teva Pharmaceutical Industries TEVA reported third-quarter 2024 adjusted earnings of 69 cents per share, which beat the Zacks ...

Teva Pharmaceutical Industries raised its 2024 revenue and earnings guidance after beating third-quarter profit forecasts, ...

Analyst Jason Gerberry of Bank of America Securities reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), boosting ...

特拉维夫 - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) 周三公布的第三季度业绩好于预期，并上调了全年指引，使其股价在盘前交易中上涨3%。

In terms of liquidity and interest, the mean open interest for Teva Pharmaceutical Indus options trades today is 8263.67 with ...

EPS, expectations were $0.66. Operator: Hello, and welcome to the Q3 2024 Teva Pharmaceuticals Industries Limited Earnings ...

As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative ...

Teva Pharmaceutical Industries expects to work productively with the incoming Trump administration in the United States, ...

On October 31, 2024, the European Commission issued a fine of €462.6 million to Teva Pharmaceuticals, citing abuse of its ...

Teva Pharmaceutical Industries Limited ( (TEVA) ) has released its Q3 earnings. Here is a breakdown of the information Teva Pharmaceutical ...

据欧盟新闻网站“欧洲动态网”11月4日报道，Teva于10月31日因滥用市场地位和违反欧盟竞争规定被处以巨额罚款。该案涉及到Teva与用于治疗多发性硬化症的成功药物Copaxone有关的反竞争行为。Teva对醋酸格拉替雷（Copaxone中的活性成分）的专利已于2015年到期。

特拉维夫 - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) 宣布将就欧盟委员会近期关于其多发性硬化症药物COPAXONE®的裁决提起上诉。该公司表示强烈反对委员会的法律理论，认为这些理论未经检验且缺乏事实支持。 这家以色列制药巨头自2019年以来一直配合欧盟委员会的调查，并准备积极为自己的立场辩护。Teva有信心在财务上支持这一法律挑战。该公司坚持 ...